Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

British Society for Rheumatology Biologics Register.

A Silman1, D Symmons, D G I Scott

  • 1ARC Epidemiology Unit, University of Manchester, UK. alan.silman@man.ac.uk

Annals of the Rheumatic Diseases
|October 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing cancer in firefighters: lessons from the Grenfell Tower fire.

Occupational medicine (Oxford, England)·2025
Same author

The impact of BMI and smoking on risk of revision following knee and hip replacement surgery: evidence from routinely collected data.

Osteoarthritis and cartilage·2019
Same author

Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study.

Scandinavian journal of rheumatology·2014
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same author

'In one ear and out the other - it's a lot to take in': a qualitative study exploring the informational needs of patients with ANCA-associated vasculitis.

Musculoskeletal care·2012
Same author

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.

Annals of the rheumatic diseases·2011
Same journal

Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.

Annals of the rheumatic diseases·2026
Same journal

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same journal

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same journal

PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.

Annals of the rheumatic diseases·2026
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
See all related articles

The British Society for Rheumatology Biologics Register (BSRBR) tracks patients with rheumatic diseases starting new biologic treatments. It monitors for short and long-term health hazards, comparing them with standard drug treatments.

Area of Science:

  • Rheumatology
  • Clinical Epidemiology
  • Pharmacovigilance

Background:

  • Biological agents represent a significant advancement in treating rheumatic diseases.
  • The long-term safety profile of these novel therapies requires ongoing monitoring.
  • Understanding potential health hazards associated with biologic treatments is crucial for patient care.

Purpose of the Study:

  • To establish and maintain the British Society for Rheumatology Biologics Register (BSRBR) for patients newly treated with biologic agents.
  • To determine the incidence of short and long-term health hazards in patients receiving biologic treatments for rheumatic diseases.
  • To recruit a comparison cohort on standard disease-modifying antirheumatic drugs (DMARDs) to isolate risks specific to biologics.

Main Methods:

Related Experiment Videos

  • Prospective cohort study design.
  • Establishment of the BSR Biologics Register (BSRBR) active since January 2002.
  • Inclusion of patients with rheumatic diseases initiating biologic therapy and a comparator group on standard DMARDs.
  • Longitudinal follow-up to assess health outcomes and adverse events.

    • Main Results:

    • The BSRBR collects data on patients initiating biologic therapies for various rheumatic conditions.
    • The register facilitates the identification of potential short and long-term adverse events associated with biologic agents.
    • A comparator cohort allows for the assessment of risks relative to conventional treatments.

    Conclusions:

    • The BSRBR is a vital resource for monitoring the safety of biologic treatments in rheumatic diseases.
    • Long-term data collection is essential for understanding the risk-benefit profile of biologic therapies.
    • Findings from the BSRBR inform clinical practice and patient safety guidelines for rheumatology.